ResMedWBO:RMD +1.27%92 Net Margin % is 27.86% as of Mar. 2026, which is 39% above its 10-year median of 20.10. GuruFocus rates WBO:RMD with a GF Score™ of 92/100 and a GF Value™ of €238.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, ResMed ranks better than 94.37% on this metric.
Net margin is calculated as Net Income divided by its Revenue. ResMed's Net Income for the
three
months ended in Mar. 2026 was €345 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was €1,238 Mil. Therefore, ResMed's net margin for the quarter that ended in Mar. 2026 was 27.86%.
The historical rank and industry rank for ResMed's Net Margin % or its related term are showing as below:
WBO:RMD'
s Net Margin % Range Over the Past 10 Years
Min: 13.49 Med: 20.1 Max: 27.44
Current: 27.44
WBO:RMD's Net Margin % is ranked better than 94.37% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs WBO:RMD: 27.44
ResMed (WBO:RMD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ResMed Net Margin % Related Terms
ResMed Net Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:RMD vs MDLN, WST, BDX: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Net Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (WBO:RMD) has a Net Margin % of 27.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ResMed and its competitors. This is 39% above median its historical median of 20.10. Over the past decade, ResMed's Net Margin % has ranged from 13.49 to 27.44. According to the industry distribution chart, ResMed ranks #46 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 5.6%.
Is ResMed's Net Margin % too high?
ResMed's current Net Margin % of 27.86% is 39% above median its 10-year median of 20.10. Over the past 10 years, this metric has ranged from a low of 13.49 to a high of 27.44. The Medical Devices & Instruments industry median Net Margin % is 2.07. ResMed's value of 27.86% is 1245.9% above this industry median. Based on the distribution chart, ResMed ranks #46 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Net Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #46 out of 817 companies for Net Margin %. This places ResMed in the top 6% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. ResMed's value of 27.86% is 1245.9% above this benchmark. Historically, ResMed's own Net Margin % has ranged from 13.49 to 27.44 over the past decade. While the company's 10-year median is 20.10 vs. the industry median of 2.07, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Net Margin % of 27.86% is 1245.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Net Margin % is 27.86%, which is 39% above median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (WBO:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is €238.90, compared to a current price of €167.55 — trading 29.9% below its estimated fair value. The current Net Margin % is 27.86%, which is 39% above median its 10-year median of 20.10 and 1245.9% above the Medical Devices & Instruments industry median of 2.07. ResMed's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ResMed (WBO:RMD), the current Net Margin % is 27.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (WBO:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of €167.55 is trading 29.9% below its estimated GF Value™ of €238.90.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for WBO:RMD:
Net Margin %: 27.86% (39% above median its 10-year median of 20.10)
GF Value™: €238.90 vs. price of €167.55 (29.9% below fair value)
Industry Position: 1245.9% above the Medical Devices & Instruments median (#46 of 817)
No single metric tells the full story. See the WBO:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
92GF Score
Get the complete analysis for WBO:RMD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:RMD has been successfully added to your 
